Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | PLA2G10 | O15496 | 6/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27695396 | 0.85 | CCR2 (0.41) | CNR2CCR2PLA2G10SLC9A1MCL1 | |
| SCHEMBL29475847 | 0.82 | PLA2G10 (0.48) | CNR2CCR2PLA2G10SLC9A1MCL1 | |
| SCHEMBL10575199 | 0.77 | LMNA (0.42) | CNR2CCR2PLA2G10SLC9A1MCL1 | |
| SCHEMBL6925634 | 0.75 | PLA2G10 (0.48) | CCR2PLA2G10SLC9A1MCL1F10 | |
| SCHEMBL27580987 | 0.74 | PLA2G10 (0.46) | CCR2PLA2G10SLC9A1MCL1F10 | |
| SCHEMBL13738783 | 0.73 | CCR2 (0.58) | CNR2CCR2PLA2G10SLC9A1MCL1 | |
| SCHEMBL30044340 | 0.73 | CCR2 (0.58) | CNR2CCR2PLA2G10SLC9A1MCL1 | |
| SCHEMBL2323444 | 0.71 | MCL1 (0.71) | PLA2G10SLC9A1MCL1DAO | |
| SCHEMBL18536897 | 0.70 | BTK (0.40) | CNR2CNR1DAO | |
| SCHEMBL2830160 | 0.70 | PLA2G10 (0.54) | CCR2PLA2G10SLC9A1MCL1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216961-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CORONAVIRUS INFECTION | Lighthouse Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066776-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CORONAVIRUS INFECTION | Cortexyme, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |